These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18436101)

  • 1. Relative mortality and epoetin alpha dose among hemodialysis patients.
    Coyne DW
    Am J Kidney Dis; 2008 May; 51(5):866-7; author reply 867. PubMed ID: 18436101
    [No Abstract]   [Full Text] [Related]  

  • 2. Relative mortality and epoetin alpha dose in hemodialysis patients.
    Cotter DJ; Thamer M; Zhang Y
    Am J Kidney Dis; 2008 May; 51(5):865; author reply 865-6. PubMed ID: 18436099
    [No Abstract]   [Full Text] [Related]  

  • 3. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
    Więcek A; Ahmed I; Scigalla P; Koytchev R
    Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin bubble: a severe German case Honi soit qui mal y pense.
    Wizemann V
    Nephrol Dial Transplant; 2011 May; 26(5):1750-2; author reply 1752. PubMed ID: 21378149
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessing the impact of concomitant therapies on anemia in dialysis patients. Case study of the anemic patient.
    Gregory N
    Nephrol Nurs J; 2000 Jun; 27(3):320-3; quiz 324-5. PubMed ID: 11249331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisions in the prescribing information for Epoetin alfa: implications for nephrology nurses and patients on dialysis.
    Hayslip D
    Nephrol Nurs J; 2008; 35(2):163-7. PubMed ID: 18472685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic kidney disease, anemia, and epoetin.
    Ashrani AA; Rajkumar SV
    N Engl J Med; 2007 Mar; 356(9):957-8; author reply 958-9. PubMed ID: 17338048
    [No Abstract]   [Full Text] [Related]  

  • 9. Anemia: dialysis patients experiences.
    Schatell D; Witten B
    Nephrol News Issues; 2004 Nov; 18(12):49-54. PubMed ID: 15595502
    [No Abstract]   [Full Text] [Related]  

  • 10. Anemia and response to epoetin alfa: the cause of anemia matters!
    Dharmarajan TS
    J Am Geriatr Soc; 2008 Aug; 56(8):1574-5. PubMed ID: 18808607
    [No Abstract]   [Full Text] [Related]  

  • 11. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.
    Cotter DJ; Stefanik K; Zhang Y; Thamer M; Scharfstein D; Kaufman J
    J Clin Epidemiol; 2004 Oct; 57(10):1086-95. PubMed ID: 15528060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hemoglobin variability in patients with chronic renal insuffiency].
    Deray G
    Nephrol Ther; 2008 Dec; 4(7):549-52. PubMed ID: 19004677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
    Singh AK
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anemia management protocols: providing consistent hemoglobin outcomes.
    Michael M
    Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of life and anemia: the nephrology experience.
    Macdougall IC
    Semin Oncol; 1998 Jun; 25(3 Suppl 7):39-42. PubMed ID: 9671329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future challenges in anaemia management.
    Levin A; Locatelli F; Muirhead N; Ritz E
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi1-2. PubMed ID: 15958819
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
    Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
    Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaemia of CKD--the CHOIR study revisited.
    Singh AK; Szczech L; Tang KL; Barnhart H; Sapp S; Wolfson M; Reddan D
    Nephrol Dial Transplant; 2007 Jul; 22(7):1806-10. PubMed ID: 17420166
    [No Abstract]   [Full Text] [Related]  

  • 19. A lesson from the EPO mess: stop the cost shifting.
    Amerling R
    Nephrol News Issues; 2007 Jul; 21(8):52, 54-5, 68. PubMed ID: 17688232
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.
    Winquist E; Julian JA; Moore MJ; Nabid A; Sathya J; Wood L; Venner P; Levine M
    J Clin Oncol; 2009 Feb; 27(4):644-6. PubMed ID: 19103725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.